Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children

Correlation between chromosomal abnormalities and prior therapy

C. M. Rubin*, D. C. Arthur, W. G. Woods, B. J. Lange, P. C. Nowell, J. D. Rowley, J. Nachman, B. Bostrom, E. S. Baum, C. R. Suarez, N. R. Shah, E. Morgan, H. S. Maurer, S. E. McKenzie, R. A. Larson, M. M. Le Beau

*Corresponding author for this work

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

We have studied 20 children with therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were 3 months to 16 years old at diagnosis of their primary neoplasm and 1 to 24 years old at diagnosis of their secondary neoplasm. The median interval from initial treatment for the first malignancy to diagnosis of therapy-related MDS or AML was 46 months (range, 12 to 116 months). Twelve patients had chromosomal abnormalities resulting in loss of material from the long arm of chromosomes 5 and/or 7, three patients had abnormalities of chromosome 11 band q23, one patient had both classes of abnormalities, three patients had other abnormalities, and one patient had a normal karyotype. Ten of 12 patients with chromosome 5 and/or 7 abnormalities had been exposed to an alkylating agent, and two of three patients with 11q23 abnormalities had been exposed to an epipodophyllotoxin. The patient with both classes of abnormalities had been exposed to both types of therapy. We conclude that abnormalities of chromosomes 5 and/or 7 are common in children with therapy-related MDS or AML. The proposed relationships between exposure to alkylating agents and abnormalities of chromosomes 5 and/or 7 and between exposure to epipodophyllotoxins and abnormalities of 11q23 are supported in this pediatric series.

Original languageEnglish (US)
Pages (from-to)2982-2988
Number of pages7
JournalBlood
Volume78
Issue number11
StatePublished - Jan 1 1991

Fingerprint

Myelodysplastic Syndromes
Chromosomes
Acute Myeloid Leukemia
Chromosome Aberrations
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Podophyllotoxin
Alkylating Agents
Therapeutics
Pediatrics
Neoplasms
Chromosomes, Human, Pair 11
Karyotype

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Rubin, C. M., Arthur, D. C., Woods, W. G., Lange, B. J., Nowell, P. C., Rowley, J. D., ... Le Beau, M. M. (1991). Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood, 78(11), 2982-2988.
Rubin, C. M. ; Arthur, D. C. ; Woods, W. G. ; Lange, B. J. ; Nowell, P. C. ; Rowley, J. D. ; Nachman, J. ; Bostrom, B. ; Baum, E. S. ; Suarez, C. R. ; Shah, N. R. ; Morgan, E. ; Maurer, H. S. ; McKenzie, S. E. ; Larson, R. A. ; Le Beau, M. M. / Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children : Correlation between chromosomal abnormalities and prior therapy. In: Blood. 1991 ; Vol. 78, No. 11. pp. 2982-2988.
@article{7f7177a762fb48d0b0732ba1285b24b2,
title = "Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy",
abstract = "We have studied 20 children with therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were 3 months to 16 years old at diagnosis of their primary neoplasm and 1 to 24 years old at diagnosis of their secondary neoplasm. The median interval from initial treatment for the first malignancy to diagnosis of therapy-related MDS or AML was 46 months (range, 12 to 116 months). Twelve patients had chromosomal abnormalities resulting in loss of material from the long arm of chromosomes 5 and/or 7, three patients had abnormalities of chromosome 11 band q23, one patient had both classes of abnormalities, three patients had other abnormalities, and one patient had a normal karyotype. Ten of 12 patients with chromosome 5 and/or 7 abnormalities had been exposed to an alkylating agent, and two of three patients with 11q23 abnormalities had been exposed to an epipodophyllotoxin. The patient with both classes of abnormalities had been exposed to both types of therapy. We conclude that abnormalities of chromosomes 5 and/or 7 are common in children with therapy-related MDS or AML. The proposed relationships between exposure to alkylating agents and abnormalities of chromosomes 5 and/or 7 and between exposure to epipodophyllotoxins and abnormalities of 11q23 are supported in this pediatric series.",
author = "Rubin, {C. M.} and Arthur, {D. C.} and Woods, {W. G.} and Lange, {B. J.} and Nowell, {P. C.} and Rowley, {J. D.} and J. Nachman and B. Bostrom and Baum, {E. S.} and Suarez, {C. R.} and Shah, {N. R.} and E. Morgan and Maurer, {H. S.} and McKenzie, {S. E.} and Larson, {R. A.} and {Le Beau}, {M. M.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "78",
pages = "2982--2988",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

Rubin, CM, Arthur, DC, Woods, WG, Lange, BJ, Nowell, PC, Rowley, JD, Nachman, J, Bostrom, B, Baum, ES, Suarez, CR, Shah, NR, Morgan, E, Maurer, HS, McKenzie, SE, Larson, RA & Le Beau, MM 1991, 'Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy', Blood, vol. 78, no. 11, pp. 2982-2988.

Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children : Correlation between chromosomal abnormalities and prior therapy. / Rubin, C. M.; Arthur, D. C.; Woods, W. G.; Lange, B. J.; Nowell, P. C.; Rowley, J. D.; Nachman, J.; Bostrom, B.; Baum, E. S.; Suarez, C. R.; Shah, N. R.; Morgan, E.; Maurer, H. S.; McKenzie, S. E.; Larson, R. A.; Le Beau, M. M.

In: Blood, Vol. 78, No. 11, 01.01.1991, p. 2982-2988.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children

T2 - Correlation between chromosomal abnormalities and prior therapy

AU - Rubin, C. M.

AU - Arthur, D. C.

AU - Woods, W. G.

AU - Lange, B. J.

AU - Nowell, P. C.

AU - Rowley, J. D.

AU - Nachman, J.

AU - Bostrom, B.

AU - Baum, E. S.

AU - Suarez, C. R.

AU - Shah, N. R.

AU - Morgan, E.

AU - Maurer, H. S.

AU - McKenzie, S. E.

AU - Larson, R. A.

AU - Le Beau, M. M.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We have studied 20 children with therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were 3 months to 16 years old at diagnosis of their primary neoplasm and 1 to 24 years old at diagnosis of their secondary neoplasm. The median interval from initial treatment for the first malignancy to diagnosis of therapy-related MDS or AML was 46 months (range, 12 to 116 months). Twelve patients had chromosomal abnormalities resulting in loss of material from the long arm of chromosomes 5 and/or 7, three patients had abnormalities of chromosome 11 band q23, one patient had both classes of abnormalities, three patients had other abnormalities, and one patient had a normal karyotype. Ten of 12 patients with chromosome 5 and/or 7 abnormalities had been exposed to an alkylating agent, and two of three patients with 11q23 abnormalities had been exposed to an epipodophyllotoxin. The patient with both classes of abnormalities had been exposed to both types of therapy. We conclude that abnormalities of chromosomes 5 and/or 7 are common in children with therapy-related MDS or AML. The proposed relationships between exposure to alkylating agents and abnormalities of chromosomes 5 and/or 7 and between exposure to epipodophyllotoxins and abnormalities of 11q23 are supported in this pediatric series.

AB - We have studied 20 children with therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who were 3 months to 16 years old at diagnosis of their primary neoplasm and 1 to 24 years old at diagnosis of their secondary neoplasm. The median interval from initial treatment for the first malignancy to diagnosis of therapy-related MDS or AML was 46 months (range, 12 to 116 months). Twelve patients had chromosomal abnormalities resulting in loss of material from the long arm of chromosomes 5 and/or 7, three patients had abnormalities of chromosome 11 band q23, one patient had both classes of abnormalities, three patients had other abnormalities, and one patient had a normal karyotype. Ten of 12 patients with chromosome 5 and/or 7 abnormalities had been exposed to an alkylating agent, and two of three patients with 11q23 abnormalities had been exposed to an epipodophyllotoxin. The patient with both classes of abnormalities had been exposed to both types of therapy. We conclude that abnormalities of chromosomes 5 and/or 7 are common in children with therapy-related MDS or AML. The proposed relationships between exposure to alkylating agents and abnormalities of chromosomes 5 and/or 7 and between exposure to epipodophyllotoxins and abnormalities of 11q23 are supported in this pediatric series.

UR - http://www.scopus.com/inward/record.url?scp=0025880799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025880799&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 2982

EP - 2988

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -

Rubin CM, Arthur DC, Woods WG, Lange BJ, Nowell PC, Rowley JD et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood. 1991 Jan 1;78(11):2982-2988.